

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and *nab*-Paclitaxel

Erin R. Gardner,¹ William L. Dahut,² Charity D. Scripture,² Jacquin Jones,² Jeanny B. Aragon-Ching,² Neil Desai,³ Michael J. Hawkins,³ Alex Sparreboom,² and William D. Figg²

Abstract Purpose: Abraxane (ABI-007) is a 130-nm albumin-bound (*nab*) particle formulation of paclitaxel, devoid of any additional excipients. We hypothesized that this change in formulation alters the systemic disposition of paclitaxel compared with conventional solvent-based formulations (sb-paclitaxel; Taxol), and leads to improved tolerability of the drug.

Patients and Methods: Patients with malignant solid tumors were randomized to receive the recommended single-agent dose of *nab*-paclitaxel (260 mg/m² as a 30-minute infusion) or sb-paclitaxel (175 mg/m² as a 3-hour infusion). After cycle 1, patients crossed over to the alternate treatment. Pharmacokinetic studies were carried out for the first cycle of sb-paclitaxel and the first two cycles of *nab*-paclitaxel.

Results: Seventeen patients were treated, with 14 receiving at least one cycle each of *nab*-paclitaxel and sb-paclitaxel. No change in *nab*-paclitaxel pharmacokinetics was found between the first and second cycles ($P = 0.95$), suggesting limited intrasubject variability. Total drug exposure was comparable between the two formulations ($P = 0.55$) despite the dose difference. However, exposure to unbound paclitaxel was significantly higher after *nab*-paclitaxel administration, due to the increased free fraction (0.063 ± 0.021 versus 0.024 ± 0.009 ; $P < 0.001$).

Conclusion: This study shows that paclitaxel disposition is subject to considerable variability depending on the formulation used. Because systemic exposure to unbound paclitaxel is likely a driving force behind tumoral uptake, these findings explain, at least in part, previous observations that the administration of *nab*-paclitaxel is associated with augmented antitumor efficacy compared with solvent-based paclitaxel.

Nab-paclitaxel (ABI-007; Abraxane) is an albumin-bound particle formulation of paclitaxel, devoid of any solvent excipients. Paclitaxel, an antimicrotubule chemotherapeutic agent currently used alone or in combination with other

anticancer drugs in the treatment of a wide range of solid tumor malignancies, is highly lipophilic and insoluble in water (1, 2). As such, it has traditionally been formulated as Taxol (sb-paclitaxel), in a mixture of Cremophor EL (polyoxyethylated castor oil) and ethanol, to allow for i.v. infusion (3). Due to the incidence of severe hypersensitivity reactions to Cremophor EL, patients are routinely pretreated with histamine blockers and steroids (4). In addition to the need for premedication, the presence of Cremophor EL has been shown to affect the pharmacokinetics of paclitaxel, due to micellar encapsulation of the drug (3). This leads to a decreased fraction of unbound drug, which limits drug distribution and clearance, and eventually results in nonlinear pharmacokinetics by decreasing the uptake of paclitaxel in RBC and tissues, thereby interfering with metabolism and biliary secretion.

Conversely, *nab*-paclitaxel can be simply dissolved in saline for infusion. An initial phase I clinical trial has shown that this drug is tolerated up to a maximum tolerated dose of 300 mg/m², administered as a 30-minute infusion, without any premedication (5). A subsequent phase II study used this dosing regimen; however, dose reductions were required in 25% of patients due to toxicity, primarily neutropenia and neuropathy (6). Therefore, the phase III study that led to Food and Drug Administration approval of *nab*-paclitaxel for treatment of metastatic breast cancer compared to a 30-minute infusion of 260 mg/m² with the standard paclitaxel regimen of 175 mg/m² as a 3-hour infusion (7). This study showed

Authors' Affiliations: ¹Clinical Pharmacology Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland; ²Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and ³Abraxis BioScience, Inc., Los Angeles, California

Received 10/9/07; revised 12/13/07; accepted 1/13/08.

Grant support: This project has been funded in whole or in part with federal funds from the National Cancer Institute, NIH, under contract N01-CO-12400 (E.R. Gardner). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The National Cancer Institute developed a Cooperative Research and Development Agreement with Abraxis Bioscience, which provided additional research funds for this study. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Current address for M.J. Hawkins: Hawkins Oncology Associates, Marina Del Ray, CA; Current address for A. Sparreboom: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, 38105.

Requests for reprints: William D. Figg, Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892. Phone: 301-402-3622; Fax: 301-402-8606; E-mail: wdfigg@helix.nih.gov.

©2008 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-07-4592

Table 1. Clinical characteristics of patients enrolled ($n = 17$)

	No
Primary diagnosis	
Metastatic prostate adenocarcinoma	11
Metastatic ovarian carcinoma	2
Metastatic breast carcinoma	3
Metastatic carcinoma of the fallopian tube	1
Gender	
Males	11
Females	6
Median age in y (range)	65 (42-76)
Race	
White	14
Hispanic	2
Asian	1
ECOG performance status (median)	
0	2
1	10
2	5
Response	
Partial response	1
Progressive disease	6
Stable disease	5
Withdrawal before response assessment	3
Death on study	2

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

significantly higher response rates and longer time to tumor progression in the group receiving *nab*-paclitaxel.

Paclitaxel has been previously shown to be highly protein bound in plasma, with Cremophor EL further decreasing the free fraction of drug (8, 9). Because the unbound fraction of paclitaxel is the pharmacologically active form, understanding factors influencing unbound paclitaxel concentrations might be important in predicting toxicity and antitumor activity. It has been hypothesized that the exclusion of this excipient will increase the unbound fraction of drug. To test this hypothesis, we evaluated the comparative pharmacokinetics of total and unbound paclitaxel after administration of *nab*-paclitaxel and sb-paclitaxel using a randomized, crossover design.

Patients and Methods

The protocol and consent form were approved by the National Cancer Institute Institutional Review Board. The study was conducted in compliance with Good Clinical Practice, guidelines of the International Conference on Harmonization, and the Declaration of Helsinki. Consent was obtained from all patients before participation.

Patient eligibility. Patients enrolled were required to have the following: (a) histologically confirmed, locally advanced or metastatic, solid tumors that were likely to be responsive to taxanes; (b) an Eastern Cooperative Oncology Group performance status of ≤ 2 ; (c) life expectancy of > 3 mo; (d) adequate bone marrow and organ function as defined by a granulocyte count of $\geq 1,500/\mu\text{L}$, platelet count of $\geq 100,000/\mu\text{L}$, total bilirubin within normal institutional limits, alanine aminotransferase and aspartate aminotransferase of $\leq 1.5 \times$ upper limit of normal, and creatinine within normal limits or measured creatinine clearance of ≥ 60 mL/min; and (e) left ventricular ejection fraction of $\geq 40\%$ without clinical signs or symptoms of heart failure. Patients who were refractory to paclitaxel or had previously untreated locally advanced breast cancer were ineligible. Patients who had a seizure

disorder requiring anticonvulsant therapy, untreated or symptomatic brain metastases, history of allergic reactions attributed to paclitaxel or Cremophor EL-containing compounds, and concomitant use of drugs or supplements known to influence the expression and function of CYP3A4 and/or CYP2C8 were excluded from the study. Other forms of concurrent antitumor therapy were prohibited.

Study design. The randomized, crossover design was selected to provide the most direct comparison of the two paclitaxel formulations, partially eliminating the effect of interindividual variability. Statistical determination of the study size was calculated using data from previous studies. The mean clearance for (unbound) paclitaxel used in the calculation is 429 L/h, estimated from a group of cancer patients treated with paclitaxel that had sampling on at least 2 occasions (10). In this group of patients, the SD of the differences of the two measurements was estimated to be 121.3. The trial was designed to detect an effect size of 107.3 per 121.3, where 107.3 is 25% of the mean of the value of the clearance from unbound paclitaxel. Based on a pair-wise (two-sided) analysis, this results in a sample size of (at least) 14 for the prospective evaluation, with a significance level of 0.05 (5%) and power of 0.86 (86%).

Up to 20 patients were allowed to be enrolled on this trial and randomized according to the order of administration of the agent, to ensure enrollment of 14 individuals who completed at least the first 2 cycles of treatment. Randomization of the patients was done by the Orkand Corp. Patients were considered evaluable for pharmacokinetics if they completed at least two treatment cycles, including a single cycle of each agent. Patients who were unable to complete a second cycle of treatment were replaced. Pharmacokinetic analyses concluded after the third cycle of therapy, but treatment with *nab*-paclitaxel was continued for patients until disease progression or toxicity was encountered.

Treatment plan. Patients were randomized to receive either 260 mg/m² *nab*-paclitaxel [Abraxane (ABI-007); Abraxis Bioscience, Inc.] as a 30-min infusion on cycle 1 day 1, followed 3 wk later in cycle 2 day 1 by 175 mg/m² sb-paclitaxel (Taxol; Bristol-Myers Squibb) as a 3-h infusion, or vice versa, followed every 3 wk thereafter by repeated treatments with 260 mg/m² *nab*-paclitaxel. Patients were premedicated with antihistamines (25-50 mg diphenhydramine i.v. and 150 mg ranitidine p.o. or i.v.) 1 h before infusion, regardless of treatment group. Although not specified in the Abraxane package insert, these were administered in all cycles to remove a possible cause of pharmacokinetic variability. In addition, during sb-paclitaxel treatment cycles, patients also received corticosteroids (20 mg dexamethasone p.o. 12 h and 6 h before the planned infusion or a single 20 mg i.v. dose 30 to 60 min before infusion). Although only administered in the sb-paclitaxel cycle, dexamethasone is unlikely to affect the pharmacokinetics of paclitaxel (11, 12). Standard blood chemistries and hematologic tests were obtained on approximately days 1, 8, 15 of cycles 1 to 3, but only hematologic tests were obtained for cycle 4 onwards on days 8 and 15. Radiographic studies (computed

Table 2. Comparison of *nab*-paclitaxel cycles 1 and 2 pharmacokinetics ($n = 12$)

	Mean ratio (cycle 2/cycle 1)	95% confidence interval	P
T _{1/2} (h)	0.93	0.76-1.10	0.28
C _{max} (ng/mL)	1.17	0.80-1.53	0.57
AUC _{INF} (h*ng/mL)	1.08	0.84-1.32	0.55
Vz_obs (L/m ²)	0.96	0.68-1.25	0.70
Cl_obs (L/h/m ²)	1.02	0.81-1.23	0.95

NOTE: Cycle 1, initial cycle of *nab*-paclitaxel—either C1 or crossover C2. Cycle 2, third overall treatment cycle.

Table 3. Comparison of total drug pharmacokinetic variables for first cycles of *nab*-paclitaxel and *sb*-paclitaxel ($n = 14$)

	<i>nab</i> -paclitaxel (260 mg/m ²)			<i>sb</i> -paclitaxel (175 mg/m ²)			<i>P</i>
	Mean	Range	%CV	Mean	Range	%CV	
T _{1/2} (h)	20.0	15.5-31.2	21.3%	20.9	15.7-34.0	21.4%	0.53
C _{max} (ng/mL)	19,556.4	10,613.1-34,201.4	36.2%	5,128.0	3,136.0-8,832.3	32.7%	<0.00001
C _{max} /dose (ng/mL per mg/m ²)	75.2	40.8-131.5	36.2%	29.3	17.9-50.5	32.7%	<0.00001
AUC _{INF} (h*ng/mL)	20,324.5	15,539.2-29,447.9	19.5%	20,821.1	12,973.4-30,622.2	25.9%	0.72
AUC _{INF_Dose} (h*ng/mL per mg/m ²)	78.2	59.8-175.0	19.5%	119.0	74.1-175.0	25.9%	0.0001
V _{z_obs} (L/m ²)	375.4	269.6-571.1	21.9%	270.8	151.0-457.2	61.4%	0.003
Cl _{obs} (L/h/m ²)	13.2	8.8-16.7	17.9%	8.9	5.7-13.5	25.7%	0.00002

Abbreviation: %CV, % coefficient of variation.

tomography scans of the chest, abdomen, and pelvis and technetium-99m bone scintigraphy for patients with known bone metastases) were done at baseline and repeated every 12 wk (after 4 cycles of treatment) to assess for response per RECIST.

Toxicity and dose modification. Toxicities were reported using the Common Toxicity Criteria for Adverse Events version 3. Dose reductions or interruptions were permitted at any time during the study after the occurrence of any dose-limiting toxicity that was not controlled by optimal supportive care or not tolerated due to symptomatology or interference with daily activities. Grade 3 or 4 events required the reduction of the subsequent dose of paclitaxel by 25% with no further dose reductions allowed beyond this level.

Sample collection and analysis. Blood samples were collected for pharmacokinetic analysis in each of the first three treatment cycles for each patient, allowing for comparison of *nab*- and *sb*-paclitaxel pharmacokinetics, in addition to evaluation of any changes in *nab*-paclitaxel pharmacokinetics with subsequent cycles. In *nab*-paclitaxel treatment cycles, ~7 mL of venous blood was obtained in a sodium heparin tube before the start of the infusion, 15 min after the start of the infusion, 2 to 5 min before the end of the infusion, and at 30 min and 1, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 h after the end of the infusion. In the *sb*-paclitaxel treatment cycle, ~7 mL of venous blood was obtained in a sodium heparin tube before the start of the infusion, 1.5 h after the start of the infusion, 2 to 5 min before the end of the infusion, and at 1, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 h after the end of the infusion. All samples were immediately centrifuged, the plasma transferred to cryovials and stored at -80°C until the time of analysis.

All samples were analyzed using an analytic assay validated for measurement of both *sb*-paclitaxel and *nab*-paclitaxel.⁴ Briefly, 100 μ L of plasma were transferred to a microcentrifuge tube, and 500 μ L of acetonitrile containing the internal standard, d₅-paclitaxel, were added. After vortex mixing, samples, along with calibrators and quality control samples prepared from blank plasma and precipitated in the same way, were transferred to a 96-well filtration plate and the precipitate was filtered out under vacuum. The collection tray was transferred to an Acquity UPLC (Waters Corp), and 10 μ L of the solution was injected. Chromatography was carried out using a Zorbax SB RP8 column (50 \times 2.1 mm), and mass detection was achieved on a Micromass Quattro Premier Triple Quadrupole Mass Spectrometer (Waters Corp). This method has been validated for quantitation of paclitaxel (formulated as either Taxol or Abraxane) in plasma within the range of 10 to

2,500 ng/mL, and each run included QC samples prepared from *nab*-paclitaxel. Within- and between-run imprecision was <9% at all QC concentrations. Accuracy error was <7%. Twenty-fold dilution analysis was also validated, allowing for measurement of sample concentrations up to 50,000 ng/mL.

For the measurement of unbound drug, 500 μ L of each sample were transferred to a Millipore Centrifree ultrafiltration device (30,000 NMWL) and centrifuged in a fixed-rotor for 30 min at 1,500 $\times g$, 20°C. After centrifugation, 100 μ L of the filtrate was treated as plasma and the standard sample preparation and analysis procedure detailed above was done.

Pharmacokinetic and statistical analysis. Noncompartmental pharmacokinetic analysis of data for each individual, per cycle, was undertaken using the software package WinNonlin, version 5.0 (Pharsight Corp). The peak plasma concentration (C_{max}) and the time to peak plasma concentration (T_{max}) are reported as observed values. The area under the plasma concentration versus time curve (AUC_{last}) was calculated using the linear trapezoidal method from time zero (at drug administration) to the time of the last sample with measurable drug concentration for each patient (C_{last}). The AUC_{inf} value was calculated by extrapolation by dividing C_{last} (the last measurable drug concentration) by the rate constant of the terminal phase. For samples with measured concentrations below the lower limit of quantitation, the measured value was used if within 20% of the lower limit of quantitation.

For unbound paclitaxel analyses, a partial AUC from the start of infusion until 4 h after the end of infusion (AUC_{0-4.5} for *nab*-paclitaxel and AUC₀₋₇ for *sb*-paclitaxel) was also calculated, to enable direct comparison of the two regimens because many plasma samples had undetectable concentrations of paclitaxel >4 h after the end of *sb*-paclitaxel infusion. The use of partial AUCs avoided the introduction of extrapolation errors.

All statistical analyses were carried out using NCSS 2004 (J. Hintze, Kaysville, UT). Outliers, defined as AUC_{inf} with >2.5-fold deviation from the mean, were excluded as stated. A *P* value of <0.05 was considered to be statistically significant in paired *t* tests.

Results

A total of 17 patients were accrued to the study from April 2005 to February 2006. The baseline clinical and biological characteristics are listed in Table 1. The median age was 65 years, and the primary diagnosis consisted of 11 patients with metastatic prostate cancer, 3 patients with metastatic breast cancer, 2 patients with metastatic ovarian cancer, and 1 with metastatic fallopian tube adenocarcinoma.

⁴ E. R. Gardner, W. Dahut, W. D. Figg. Quantitative determination of total and unbound paclitaxel in human plasma after treatment with ABI-007. *J Chrom B Analyst. Technol Biomed Life Sci* 2008;862:213-8.

Table 4. Comparison of unbound paclitaxel pharmacokinetic variables for first cycles of *nab*-paclitaxel and sb-paclitaxel ($n = 14$)

	<i>nab</i> -paclitaxel (260 mg/m ²)			sb-paclitaxel (175 mg/m ²)			<i>P</i>
	Mean	Range	%CV	Mean	Range	%CV	
C _{max} (ng/mL)	1,283.7	419.3-2,401.9	41.5%	121.8	65.9-198.3	32.5%	<0.000001
C _{max} /dose (ng/mL per mg/m ²)	4.9	1.6-9.2	41.5%	0.7	0.4-1.1	32.5%	<0.000005
AUCINF (h*ng/mL)	1,158.8	636.6-1,759.4	29.1%	409.9	207.3-649.3	35.0%	<0.000005
AUCINF_Dose (h*ng/mL per mg/m ²)	4.5	2.5-6.9	27.4%	2.3	1.2-3.7	35.0%	0.0002
AUC 0-4.5 (h*ng/mL)	969.2	355.0-1,661.9	32.9%				0.0002
AUC 0-7 (h*ng/mL)				361.1	193.2-589.0	32.3%	

Eight patients were randomized to receive *nab*-paclitaxel and 9 patients to receive sb-paclitaxel, in the first cycle. All 17 patients had at least one cycle of treatment. Of the 17 patients, 14 proceeded to cycle 2. Two patients, one on each arm, died within 2 and 3 weeks of administration of cycle 1 of sb-paclitaxel and *nab*-paclitaxel, respectively. Both of these patients had a performance status of 2 at the time of enrollment. The patient who received sb-paclitaxel had a diagnosis of metastatic ovarian cancer and died of complications from small bowel obstruction, related to the primary diagnosis. The second patient, with a diagnosis of metastatic prostate cancer, had failure to thrive after the first cycle of *nab*-paclitaxel treatment but already had debilitation secondary to bone pain upon study enrollment and died thereafter. The third patient who received only one cycle of treatment (sb-paclitaxel arm) discontinued treatment secondary to dyspnea and requested to come off study secondary to inability to travel. All other patients were treated and included in the assessment for toxicity and pharmacokinetic analyses.

***nab*-paclitaxel pharmacokinetics.** Thirteen patients completed multiple cycles of treatment with *nab*-paclitaxel, but one patient was deemed an outlier and excluded from the analysis. There was no statistically significant difference between the paired pharmacokinetic data, and the mean clearance remained unchanged between the first (either C1 or crossover C2) and

second (C3) cycles of *nab*-paclitaxel (13.15 versus 13.24 L/h/m²; $P = 0.95$; Table 2).

Comparison of *nab*-paclitaxel and sb-paclitaxel pharmacokinetics. The observed peak plasma concentration of paclitaxel was 3.8-fold higher after administration of 260 mg/m² of *nab*-paclitaxel, compared with 175 mg/m² of sb-paclitaxel (19,556.42 ± 7,070.93 versus 5,127.96 ± 1,678.65 ng/mL; $P < 0.001$; Table 3). However, overall total drug exposure was comparable between the regimens (20,324.49 ± 3,965.89 h*ng/mL after *nab*-paclitaxel versus 20,821.07 ± 5,391.37 h*ng/mL after sb-paclitaxel; $P = 0.72$). As such, dose-normalized total drug exposure was higher after sb-paclitaxel, presumably due to considerably slower paclitaxel clearance after administration of the sb-paclitaxel formulation (8.94 ± 2.30 versus 13.21 ± 2.37 L/h/m², respectively; $P = 0.00002$).

Unbound paclitaxel pharmacokinetics. As expected, the mean fraction unbound of paclitaxel was considerably higher with *nab*-paclitaxel compared with sb-paclitaxel (0.063 ± 0.021 versus 0.024 ± 0.009; $P < 0.001$; Table 4). In comparison, previous studies have shown that paclitaxel spiked into blank plasma (without Cremophor EL) has a free fraction of ~0.08 or greater (13, 14). This increase in free fraction, coupled with the higher dose and shorter infusion time, led to a maximal concentration of unbound paclitaxel ~10-fold higher after *nab*-paclitaxel administration (1,283.7 ± 532.17 versus 121.79




Fig. 1. Unbound paclitaxel concentration-time profiles after *nab*-paclitaxel (A) or sb-paclitaxel (B) administration, for all 14 individuals.

± 39.62 ng/mL). In many individuals, plasma concentrations of unbound paclitaxel dropped below the limit of quantitation of the assay within 10 hours after sb-paclitaxel infusion (Fig. 1). As such, partial AUCs were calculated, from the start of infusion until 4 hours after infusion for each drug, to allow direct comparison. The mean unbound paclitaxel exposure up to 4 hours postinfusion was significantly higher (~2.7-fold) after nab-paclitaxel (AUC_{0-4.5_{nab-paclitaxel}} 969.20 ± 318.82 versus AUC_{0-7_{sb-paclitaxel}} 361.08 ± 116.54 h*ng/mL; P = 0.00002). Comparison of dose-normalized unbound drug exposure, up to 4 hours postinfusion, was also ~80% higher with nab-paclitaxel (P = 0.0007).

Toxicity. All patients who received treatment were evaluated for toxicity. Hematologic toxicities were the main adverse events in both arms. Grade 3 neutropenia occurred in two patients while receiving nab-paclitaxel and three patients receiving sb-paclitaxel. However, grade 4 neutropenia was experienced by two patients in the nab-paclitaxel arm only (Table 5). Febrile neutropenia occurred in 2 patients, one in cycle 1 of nab-paclitaxel and the other during cycle 3 of nab-paclitaxel. Nonhematologic toxicities occurred in 38% of

patients and included nausea, vomiting, alopecia, diarrhea, and increased partial thromboplastin time (PTT). In the first cycle of treatment, grade 1 and 2 fatigue occurred only in the sb-paclitaxel arm (25% versus 0%); however, similar incidence of fatigue was noted in subsequent cycles of nab-paclitaxel. The incidence of sensory neuropathy did not differ between the two regimens during cycle 1 (13% versus 12.5%).

Response to therapy. Of the 14 remaining patients who received at least one cycle of sb-paclitaxel and at least one cycle of nab-paclitaxel, only 12 patients were evaluated for response due to withdrawal from study before the scheduled response assessment. Partial response was documented in one patient with metastatic prostate cancer. Stable disease was documented in five patients: two patients with a diagnosis of metastatic breast cancer and three patients with metastatic prostate cancer. The median duration of stable disease was 7.2 months (range, 2.9-8.6), with these patients receiving a median of 10 treatment cycles (range, 3-16). Overall, patients received a median of 4 cycles (range, 1-16), including the first two crossover cycles. None had a complete response to treatment and the rest had progressive disease.

Table 5. Incidence of treatment-related adverse events

Toxicity	Cycle 1 and crossover cycle 2 ABI-007 (n = 15)						Cycle 1 and crossover cycle 2 Taxol (n = 16)						Cycle 3 ABI-007 and beyond (n = 13)							
	Grade 1-2		Grade 3		Grade 4		Grade 1-2		Grade 3		Grade 4		Grade 1-2		Grade 3		Grade 4			
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%		
Body as a whole																				
Alopecia	5	33					6	37.5												
Anorexia/weight loss	1	7					2	12.5					1	8						
Arthralgia/Pain	2	13					2	12.5					3	23						
Fatigue							4	25					4	31						
Headache	2	13					1	6					1	8						
Hypersensitivity reaction															1	8				
Blood/bone marrow changes																				
Anemia	1	7	1	7			1	6					2	15	2	15				
Thrombocytopenia															2	15				
Leukopenia	1	7	1	7	1	7	4	25	2	12.5					2	15	1	8		
Neutropenia			2	13	2	13	1	6	3	19			1	8	2	15	3	23		
Lymphopenia			3	20	1	7			2	12.5					1	8				
Febrile neutropenia			1	7											1	8				
Digestive system																				
Mucositis	2	13					1	6												
Nausea/vomiting	5	33					2	12.5					5	38						
Diarrhea	1	7					2	12.5	1	6			1	8						
Dyspepsia							2	12.5												
Dysgeusia	2	13					1	6					3	23						
Flatulence/adominal distention	1	7	1	7																
Pulmonary/cardiovascular system																				
Dyspnea	1	7									1	6								
Nervous/muscular system																				
Dizziness	1	7					2	12.5					2	15						
Neuropathy:sensory	2	13					2	12.5					2	15	1	8				
Muscle weakness							1	6	1	6										
Metabolic/laboratory abnormalities																				
Increased PTT			1	7			2	12.5	1	6			1	8						
Hypermagnesemia															2	15				
Hypocalcemia													1	8	2	15				
Hypophosphatemia									1	6										
Hypokalemia															1	8				

Discussion

This trial was designed to assess the effects of a change in paclitaxel formulation, namely, the elimination of Cremophor EL as an excipient, on the resulting pharmacokinetics and toxicity, in patients with metastatic solid tumors.

Comparison of total drug exposure showed that although higher initial concentrations of paclitaxel were observed after *nab*-paclitaxel (due to increased dose and shortened infusion time) compared with *sb*-paclitaxel, the increased clearance results in similar systemic exposure. These pharmacokinetic variables, including the similarity in terminal half-life, are in accord with previously published data (15). In this study, the use of a crossover design eliminated the possibility that clearance differences between the two formulations arose due to difference in the patient population in each arm. Furthermore, we did not observe an increase in interindividual pharmacokinetic variability with *nab*-paclitaxel compared with *sb*-paclitaxel.

We have recently shown augmented antitumor activity of paclitaxel with *nab*-paclitaxel in preclinical mouse xenograft models (16), which was supported by data showing increased intratumoral concentrations and increased binding to, and transport across, endothelial cells (17). This finding seems to be in part due to the ability of Cremophor EL to inhibit binding of paclitaxel to endothelial cells. However, it is highly possible that the 2.7-fold increase in unbound drug exposure we observed with the *nab*-paclitaxel formulation plays a role in the increased response, simply by allowing for greater drug

distribution, a possibility that is supported by the increased volume of distribution, compared with *sb*-paclitaxel. What remains unclear is why this increase in free drug has not resulted in greater toxicity in other clinical studies, as unbound drug exposure or time above a threshold has been linked to hematologic toxicity (18).

In contrast to the larger phase III study, which, despite the higher dose, showed decreased grade 4 neutropenia after *nab*-paclitaxel compared with *sb*-paclitaxel, we observed the opposite (13% versus 0% for the first cycle, with a 23% incidence rate in later cycles of *nab*-paclitaxel; ref. 7). However, the current study was not statistically powered for comparison of toxicity between the two regimens.

Overall, this study shows that paclitaxel disposition is subject to considerable variability depending on the formulation used. Because systemic exposure to unbound paclitaxel is likely a driving force behind tumoral uptake, these findings explain, at least in part, previous observations that the administration of *nab*-paclitaxel is associated with augmented antitumor efficacy compared with *sb*-paclitaxel. The experimental design applied here may provide a template for future evaluation of pharmacokinetic comparisons of alternate paclitaxel formulations.

Disclosure of Potential Conflicts of Interest

N. Desai and M. Hawkins were employed by Abraxis BioScience. No other potential conflicts of interest were disclosed.

References

1. Taxol (paclitaxel) injection -Package Insert. Princeton (NJ): Bristol-Myers Squibb Co.
2. Wani M, Taylor H, Wall M. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc* 1971;93:2325-7.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. *Eur J Cancer* 2001;37:1590-8.
4. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. *Clin Pharmacokinet* 2003;42:665-85.
5. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. *Clin Cancer Res* 2002;8:1038-44.
6. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. *J Clin Oncol* 2005;23:6019-26.
7. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23:7794-803.
8. Brouwer E, Verweij J, De Bruijn P, et al. Measurement of fraction unbound paclitaxel in human plasma. *Drug Metab Dispos* 2000;28:1141-5.
9. Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. *J Clin Oncol* 2002;20:574-81.
10. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. *J Clin Oncol* 2001;19:4065-73.
11. Bruno N, Vivier C, Houver G, Montay G, Riva A. Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics. *Ann Oncol* 1996;7:A335.
12. Bun SS, Giacometti S, Fanciullino R, Ciccolini J, Bun H, Aubert C. Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. *Anticancer Drugs* 2005;16:675-82.
13. van den Bongard HJ, Kemper EM, van Tellingen O, et al. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. *Anal Biochem* 2004;324:11-5.
14. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nuijten WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. *Br J Cancer* 1999;81:330-5.
15. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). *Clin Cancer Res* 2005;11:4136-43.
16. Ng SS, Sparreboom A, Shaked Y, et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. *Clin Cancer Res* 2006;12:4331-8.
17. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clin Cancer Res* 2006;12:1317-24.
18. Henningsson A, Sparreboom A, Sandstrom M, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. *Eur J Cancer* 2003;39:1105-14.